Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Sethi

Showing results (151-160 of 206) with videos related to

Pageof 21
Sort By:
Data in Brief|September 20, 2019
Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary diseaseJames Donohue, Edward Kerwin, Sanjay Sethi, et al.
Infection and Immunity|August 6, 2008
Serial isolates of persistent Haemophilus influenzae in patients with chronic obstructive pulmonary disease express diminishing quantities of the HMW1 and HMW2 adhesinsDeborah M Cholon, David Cutter, Stephen K Richardson, et al.
Plos One|September 5, 2025
Leveraging dynamic stability to infer regulation in protein-protein interaction networks: A study of infectious vulnerability in COPDJoyce Reimer, Jeffrey Page, Pranta Saha, et al.
COPD|August 2, 2008
COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early interventionMarc Decramer, Stephen Rennard, Thierry Troosters, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 10, 2019
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPDSanjay Sethi, Edward Kerwin, Henrik Watz, et al.
Respiratory Medicine|June 1, 2019
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseJames F Donohue, Edward Kerwin, Sanjay Sethi, et al.
Respiratory Research|November 1, 2019
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)James F Donohue, Edward Kerwin, Sanjay Sethi, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 31, 2016
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study designStephen I Rennard, Fernando J Martinez, Klaus F Rabe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 28, 2010
Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measureNancy Kline Leidy, Teresa K Wilcox, Paul W Jones, et al.
Respiratory Research|October 8, 2014
Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trialsNancy K Leidy, Lindsey T Murray, Brigitta U Monz, et al.
Pageof 21

Showing results (151-160 of 206) with videos related to

Sort By:
Pageof 21
Data in Brief|September 20, 2019
Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary diseaseJames Donohue, Edward Kerwin, Sanjay Sethi, et al.
Infection and Immunity|August 6, 2008
Serial isolates of persistent Haemophilus influenzae in patients with chronic obstructive pulmonary disease express diminishing quantities of the HMW1 and HMW2 adhesinsDeborah M Cholon, David Cutter, Stephen K Richardson, et al.
Plos One|September 5, 2025
Leveraging dynamic stability to infer regulation in protein-protein interaction networks: A study of infectious vulnerability in COPDJoyce Reimer, Jeffrey Page, Pranta Saha, et al.
COPD|August 2, 2008
COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early interventionMarc Decramer, Stephen Rennard, Thierry Troosters, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 10, 2019
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPDSanjay Sethi, Edward Kerwin, Henrik Watz, et al.
Respiratory Medicine|June 1, 2019
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseJames F Donohue, Edward Kerwin, Sanjay Sethi, et al.
Respiratory Research|November 1, 2019
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)James F Donohue, Edward Kerwin, Sanjay Sethi, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 31, 2016
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study designStephen I Rennard, Fernando J Martinez, Klaus F Rabe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 28, 2010
Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measureNancy Kline Leidy, Teresa K Wilcox, Paul W Jones, et al.
Respiratory Research|October 8, 2014
Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trialsNancy K Leidy, Lindsey T Murray, Brigitta U Monz, et al.
Pageof 21